跳至主要内容
临床试验/NCT00053846
NCT00053846已完成2 期

Buspirone in Reducing Shortness of Breath in Patients With Cancer

University of Rochester15 个研究点 分布在 1 个国家目标入组 432 人开始时间: 2002年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
432
试验地点
15
主要终点
Dyspnea as Measured by Oxygen Cost Diagram (OCD)

研究概览

简要总结

RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy.

PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer.

详细描述

OBJECTIVES:

  • Assess the degree to which buspirone can decrease the sensation of dyspnea in patients with malignant disease.
  • Estimate the incidence of dyspnea in patients seen in community oncology practice settings.
  • Investigate interrelationships of fatigue, depression, anxiety, and patient report of dyspnea.
  • Assess the quality of life of patients treated with this drug.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to participating center (CCOP site). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Beginning on day 7 of chemotherapy, patients receive oral buspirone once a day for 3 days and then twice daily for up to 28 days.
  • Arm II: Patients receive oral placebo as in arm I. Dyspnea is assessed at baseline. Dyspnea, mood, fatigue, depression, anxiety, and quality of life are assessed within 5-7 days before chemotherapy and immediately following therapy.

PROJECTED ACCRUAL: A total of 376 patients (188 per treatment arm) will be accrued for this study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

buspirone hydrochloride

Experimental

buspirone hydrochloride

干预措施: buspirone hydrochloride (Drug)

Placebo

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Dyspnea as Measured by Oxygen Cost Diagram (OCD)

时间窗: 28 days after beginning study drug or placebo

OCD was used to evaluate dyspnea on exertion and activities of daily living. OCD is a visual analog scale for quantifying a patient's evaluation of tolerance of exertion, which corresponds to oxygen requirements at different activity levels. It is measured as a score of 2 (sleeping) to 14 (brisk walking uphill). HIgher scores indicate fewer limitations due to dyspnea.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gary Morrow

Director, URCC CCOP Research Base

University of Rochester

研究点 (15)

Loading locations...

相似试验